Small molecule inhibition of CBP/catenin interactions eliminates drug resistant clones in acute lymphoblastic leukemia

@inproceedings{Gang2014SmallMI,
  title={Small molecule inhibition of CBP/catenin interactions eliminates drug resistant clones in acute lymphoblastic leukemia},
  author={Eun Ji Gang and Y T Hsieh and Jennifer Pham and Yi Zhao and Cu Nguyen and Sandra Huantes and Eugene Park and Khatija Naing and Lars Klemm and Srividya Swaminathan and Edward M Conway and Louis M. Pelus and John D. Crispino and Charles G Mullighan and M Katharine McMillan and Markus M{\"u}schen and Michael Kahn and Yong-Mi Kim},
  booktitle={Oncogene},
  year={2014}
}
Drug resistance in acute lymphoblastic leukemia (ALL) remains a major problem warranting new treatment strategies. Wnt/catenin signaling is critical for the self-renewal of normal hematopoietic progenitor cells. Deregulated Wnt signaling is evident in chronic and acute myeloid leukemia; however, little is known about ALL. Differential interaction of catenin with either the Kat3 coactivator CREBBP (CREB-binding protein (CBP)) or the highly homologous EP300 (p300) is critical to determine… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

MYCN is a novel oncogenic target in adult B‐ALL that activates the Wnt/β‐catenin pathway by suppressing DKK3

Journal of cellular and molecular medicine • 2018
View 13 Excerpts
Highly Influenced

Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.

Cold Spring Harbor perspectives in medicine • 2017
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Similar Papers

Loading similar papers…